t-cell Europe announces first-round financing of €1.45m

t-cell Europe — a spin-off from the Berlin-Brandenburg Center for Regenerative Therapies — has completed first-round financing, raising a total of €1.45m (£1.16m).

Funding has been received from Germany’s High-Tech Gruenderfonds, Constantin Bastian Leander Venture Capital, and the Brandenburg state development bank (ILB).

The start-up company has dedicated itself since its founding in 2010 to the development and subsequent commercialisation of T-cell-based therapies.

Its first product for a specific medical indication — a T-cell product for use in conjunction with kidney transplants — is currently being developed on the basis of the company’s internally developed and patent-protected platform technology.